Identification of single nucleotide polymorphisms in the p21


















































Longevity in humans is believed to be a multifactorial 
condition   to  which  both   genetic  and   environmental  
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factors  are likely to contribute.  Centenarians are often  
spared from age-related diseases, such as cardiovascular 
disease, Alzheimer’s disease, diabetes mellitus, and 
cancer. The rate of aging and maximum lifespan varies 
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be at least in part under genetic control [1-2]. 
Epidemiological data indicate the presence of a strong 
familiar component of longevity that is largely 
determined by genetics. Thus, progeroid syndromes of 
accelerated aging have known genetic causes [3-4]. A 
number of possible associations between longevity and 
allelic variants of genes have been described. Estimates 
of the heritability of human lifespan vary from 10-50% 
with the most common finding being that about a third 
of human lifespan may be heritable. The rest is due to 
environmental exposure, accidents and injuries, lifestyle 
and chance. Very long life, to beyond the age of 90 
years, appears to have an even stronger genetic basis 
[5], which explains why centenarians and near-
centenarians tend to cluster in families. 
 
Theories on aging postulate that aging is a remodeling 
process, where the body of survivors progressively 
adapts to internal and external damaging agents, to 
which they are exposed over several decades. Thus, 
stress response and adaptation mechanisms play a 
fundamental role in the aging process and have an 
impact on individual lifespan.  Centenarians’ capability 
to live such extraordinarily long lives is in large part 
due to genetic variations that either affect the rate of 
aging or decrease the susceptibility to age-associated 
diseases.  
 
Some of the most promising candidate genes appear to 
be those involved in stress response. An interesting 
possible candidate is p21 (CDKN1A) which has been 
shown to be involved both in stress response 
mechanisms and in the expression of genes implicated 
in age-related diseases. p21 is best known as a stress-
inducible cyclin-dependent kinase inhibitor, which 
triggers cell growth arrest associated with senescence 
and damage response. Some evidence suggests that the 
effects of p21 induction
 on gene expression in senescent 
cells may contribute to the pathogenesis
 of cancer and 
age-related
 diseases. In particular, p21 expression was 
found to upregulate
 multiple genes that have not only 
been associated with senescence but also implicated
 in 
age-related diseases, including Alzheimer's
  disease, 
atherosclerosis, amyloidosis, arthritis and cancer, thus 
suggesting  that p21 induction by stress may play a 
causal role in these diseases [6]. The role of p21 in cell 
senescence and its possible implication in the risk of
 
age-related diseases suggests that allelic variations in 
this gene may have an impact on the lifespan. The goal 
of this study was to identify p21 polymorphisms and to 







To determine if any polymorphic variants of p21 that 
change either its amino acid sequence or regulation of 
its transcription may be differentially represented in the 
long lived individuals (LLI), we carried out this study in 
several steps. First, in the pilot study, we sequenced the 
three exons of the p21 gene and a 5-kb stretch of its 
promoter sequence in the DNA from ten LLI > 90 y.o. 
(Americans of European descent) to identify SNPs in 
these regions. To determine if the identified SNPs are 
specific for LLI, we then used the Sequenom SNP 
analysis strategy to determine the frequencies of these 
SNPs in a population of 92 non-LLI individuals 
(Utah/CEPH population). Finally, in the ethnicity-
matched large scale analysis, we used the Sequenom 
strategy to determine the frequencies of p21 SNPs in 
ethnically matched Italian populations of 184 LLI and 
184 non-LLI control subjects. 
 
SNPs of the p21 promoter identified by sequence 
analysis 
 
As the first approach, we undertook the sequencing of 
the three p21 exons and a 5-kb sequence upstream of 
the p21 transcription start site in the genomic DNA 
from ten LLI. Comparison with the human genome 
database sequence revealed only one SNP within the 
three exons, an A->C transversion in codon 31 causing 
Arg -> Ser substitution (rs1801270). This SNP was 
previously known and the frequency of the minor allele 
among the LLI was 0.28 (5/18), which was similar to 
the minor allele frequency of 0.24 in the general 
population (unstratified for ethnicity), reported at that 
time for this SNP in the NCBI database. Promoter 
sequencing yielded a total of 29 SNPs. Only six of the 
promoter SNPs had known frequencies reported in the 
NCBI database, 17 others had been reported but not 
characterized, and six other promoter SNPs had not 
been previously reported. To determine the frequencies 
of the promoter SNPs in a non-LLI population, 25 of 
these SNPs were assayed in 92 younger Utah/CEPH 
individuals using Sequenom MassARRAY® system. 
The positions and allele frequencies for all the SNPs 
identified in the promoter are presented in Table 1.   
Notably, we found ten SNPs that were strongly 
associated with each other in the Utah/CEPH population  
(rs4711458, rs471459, rs4711461, rs4714002, rs471146, 
rs4714003, rs56850951, rs10947623, rs12192827, 
rs12192877), in the region between -4547 bp and -3489 
bp,  where a novel p53  binding site  has been  recently 
found [7]. We have found that a cluster of minor alleles  
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the ten LLI samples compared to the Utah/CEPH 
population. The frequencies of the rare allele-carriers 



















































and 23% for the Utah/CEPH population. This difference 
did not reach statistical significance (P< 0.158 t-test). No 
significant differences between these two populations 



























































rare allele      
in LLI 
 Frequency of 




rs4711458  36749919 C  0.25 0.115 T 
rs4711459  36750002 C  0.25 0.115    T 
rs4711461  36750146 T  0.25 0.098 C 
rs4714002  36750164 T  0.25 0.885 G 
rs471146  36750168 A  0.25 0.904 G 
rs4714003  36750238 T    0.25 0.119 C 
rs56850951  36750380 T  0.25  NA  C 
rs10947623  36750814 A  0.22 0.118 G 
rs12192827  36750949 T  0.27 0.120 C 
rs12192877  36750977 A  0.25 0.080 C 
CDKN1A11  36751056  G       0.10  0.070  A 
CDKN1A12 36751203  G  0.25    NA  A 
CDKN1A13 36751481  A  0.11  0.000  G 
rs9394371 36751733  T  0.11  0.110  C 
rs4135234 36752199  A  0.12  0.070  G 
rs3829963 36752364  A  0.27  0.100  C 
rs3829964 36752475  C  0.45  0.400  T 
rs3829965 36752488  G  0.27  0.110  A 
rs4135237 36752868  T  0.25  0.000  G 
rs3829966 36752929  T  0.07  0.070  C 
rs3829967 36752936  C  0.07  0.100  T 
rs3829968 36752943  C  0.07  0.070    T 
rs733590 36753181  C  0.06  0.000  T 
rs762623 36753444  A  0.31  0.290  G 
rs2395655 36753674  G  0.27  0.320  A 
rs730506 36753946  C  0.11  0.190  G 
rs4151702 36753966  C  0.11  0.200  G 
rs4135239 36754331  C  0.13  NA  G 
CDKN1A29  36754348   +C  1.00  NA    
Table 1. Summary of statistics for SNPs identified in the pilot study. 
Strongly associated SNPs in the Utah/CEPH population are shown in italics. 
   



























A cluster of minor alleles in the p21 promoter does 
not alter its basal activity and p53 responsiveness  
 
Since ten rare SNPs within the region between -4547 bp 
and -3489 bp, comprising a p53 binding site, were 
found at a higher frequency among the ten LLI relative 
to the Utah/CEPH population, we were interested to 
determine if the presence of these minor alleles affects 
the basal activity or p53 dependence of the p21 
promoter. A 2.1-kb fragment containing a cluster of the 
minor alleles in this region was amplified by PCR from 
the genomic DNA of one LLI and cloned into the 
plasmid p21-PGL.4.10-luc-, which contains 5 kb of the 
p21 promoter driving the expression of the firefly 
luciferase reporter gene [7], replacing the common 
alleles in the corresponding promoter region. The 
resulting plasmid was designated p21R-Luc. To 
compare the basal activities of the rare-allele p21R-Luc 
and the common-allele p21-PGL.4.10-luc construct 
(designated p21C-Luc in Fig. 1), three independent 
preparations of each plasmid were transfected into wild-
type HCT116 colon carcinoma cells, together with a 
Renilla luciferase expressing vector (normalization 
standard). Normalized firefly luciferase expression from 
the two plasmids was indistinguishable, indicating 
unaltered basal activity of the LLI-derived promoter 





































the p21 promoter could have a different response to 
p53, we transfected one preparation of each plasmid 
into wild-type HCT116 cells and into the HCT116 
derivative with the knockout of both p53 alleles [8]. The 
two plasmids showed equal (two-fold) reduction in the 
promoter activity in p53-knockout cells (Figure 1B), 
indicating that the LLI-derived promoter had essentially 
unaltered response to p53.  
 
Large scale analysis of p21 SNPs: correlations with 
longevity in the Italian population  
 
A comparison of allelic frequencies between the first 
two population samples that we analyzed, ten LLI from 
Americans of European origin and younger individuals 
of the Utah/CEPH population, is inevitably biased by 
the small sample size of the LLI set and by historically 
limited variability in the founder pool of the Utah 
population. Consequently the SNP frequencies could be 
affected not only by longevity but could also have the 
founder pool as an uncontrolled confounder. This is an 
issue typical in genetic association studies affected by 
the phenomena of ‘stratification’: the failure to 
adequately match the genetic background of cases and 
controls. Therefore, to minimize this problem, in the 
large scale analysis we only used DNA from 
centenarians (mean age 100.88±1.77 years) and younger  
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(184 subjects each), selected for similar origins in 
Central Italy and representing ethnically matched 
populations.  We undertook this large case-control 
design study to (i) verify frequencies of the SNPs 


















































of 60,000 bp, and (iii) determine whether any specific 
SNPs and haplotypes are associated with longevity. In 
addition to 17 of our SNPs identified in the pilot study, 
30 SNPs spanning the p21 gene were selected from the 
SNP HapMap consortium database, for a total of 47 
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P     OR 
rs6457931 36721790  G  0.450  0.447  T  0.006  0.936  1.014 
rs1321312 36730852  G  0.155  0.198  C  1.790  0.181  0.746 
rs4331968 36731221  T  0.299  0.282  A  0.200  0.655  1.086 
rs9470367 36734910  C  0.323  0.321  G  0.004  0.949  1.012 
rs6920453 36735461  T  0.228  0.207  C  0.382  0.537  1.134 
rs9462209 36736020  G  0.466  0.411  T  1.452  0.228  1.254 
rs4713999  36741047  A 0.413  0.459  G 1.098  0.295  0.829 
rs1321309 36746614  T  0.440  0.400  C  0.965  0.326  1.177 
rs4711459 36750002  C  0.153  0.139  T  0.200  0.655  1.115 
rs4711461 36750146  T  0.163  0.136  C  0.826  0.364  1.238 
rs4714003 36750238  T  0.086  0.092  C  0.072  0.789  0.921 
CDKN1A  36750804  G 0.156  0.181  A 0.667  0.414  0.834 
rs10947623  36750814  A 0.165  0.126  G 1.652  0.199  1.366 
rs12192827 36750949  T  0.156  0.122  C  1.367  0.242 1.332 
rs12192877 36750977  A  0.158  0.134  C  0.679  0.410 1.218 
rs4135234  36752199  A 0.151  0.180  G 0.895  0.344  0.809 
rs3829963 36752364  A  0.135  0.136  C  0.002  0.969  0.990 
rs3829965  36752488  G 0.161  0.142  A 0.378  0.539  1.158 
rs4135237 36752868  T  0.158  0.171  G  0.160  0.689  0.913 
rs3829966 36752929  T  0.146  0.169  C  0.586  0.444  0.839 
rs3829967 36752936  C  0.261  0.212  T  1.974  0.160  1.313 
rs733590 36753181  C  0.452  0.458  T  0.025  0.875  0.973 
rs762623  36753444  A 0.161  0.188  G 0.705  0.401  0.827 
rs2395655  36753674  G 0.479  0.504  A 0.335  0.563  0.904 
rs730506 36753946  C  0.245  0.252  G  0.035  0.852  0.964 
rs4151702 36753966  C  0.257  0.254  G  0.008  0.930  1.017 
rs3176343 36758245  A  0.044  0.075  G  2.597  0.107  0.561 
rs3176344 36758525  A  0.018  0.043  G  3.069  0.080  0.396 
rs3176349 36759355  T  0.028  0.053  G  2.091  0.148  0.526 
rs1801270  36759949  A 0.043  0.093  C 5.412  0.020  0.437 
rs1059234 36761575  T  0.049  0.098  C  4.983  0.026  0.472 
rs876581 36763423  A  0.056  0.092  G  2.653  0.103  0.583 
























Of those markers, 45 had high confidence calls on the 
platform and two markers (CDKN1A29 and rs4711458) 
were excluded because of the low call-rate. Of the 
remaining SNPs, four (rs4711458, rs4714003, 
CDKN1A7, rs6920453) were eliminated because the 
genotype frequencies were not consistent with Hardy-
Weinberg equilibrium in the control dataset or in the 
entire sample. The association statistics for the 
remaining 41 SNPs are presented in Table 2. Haplotype 
frequencies were estimated using a sliding window 
approach. Linkage disequilibrium (LD) analysis of the 
p21 gene revealed the presence of seven blocks of 
haplotype in the 60,000 bp region studied. Figure 2 
shows a graphical representation of the blocks 
identified. SNP analysis revealed the presence of two 
minor alleles that were underrepresented in the LLI 
compared to the non-LLI control populations, at SNPs 
rs1801270 and rs1059234. Remarkably, these were the 
only two exonic SNPs of all the SNPs analyzed. The 
above mentioned rs1801270 consists of a base change 
from AGC to AGA and amino acid changes from serine 
to arginine at codon 31 in exon 2. SNP rs1059234 
(p21C70T) consists of a C to T change in the 3' 
untranslated region of the p21 gene, 20 bp following the 
stop codon. Minor allele frequencies of SNP rs1801270 
were 0.093 and 0.043 in controls and LLI respectively 
(P< 0.02 chi-test). The corresponding minor allele 
frequencies for SNP rs1059234 were 0.098 and 0.049 
(P< 0.026 chi-test). No statistically significant 
frequency differences were observed between LLI and 






















P value  SNPs 
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SNPs rs1801270 and rs1059234 are in LD and comprise 
the sixth LD block in the gene (which includes SNPs 
rs3176343, rs3176344, rs3176349, rs1801270, 
rs1059234, rs876581, rs6457938 and rs6457940). Table 
3 shows analysis of haplotype structure using tagSNP 
and estimated haplotype frequencies in this sixth block. 
A 6-SNP haplotype comprising rs1801270 and 
rs1059234 common alleles (GGGCCG) is more 
prevalent in the LLI individuals compared to the 
controls (91.0% vs 82.0%; p<0.002); the corresponding 
frequencies for the 4-SNP haplotype of common alleles 
are 90.4% vs. 81.9% (p<0.004). The significance of 





In the present study, we have investigated possible 
associations between longevity and SNPs in the p21 
(CDKN1A) gene, which plays a role in stress response 
and cell senescence, and increased expression of which 
was shown to upregulate genes implicated in several 
age-related diseases [6]. By sequencing the three exons 
and 5 kb of the promoter region of p21, we have 
identified many previously unknown or uncharacterized 
SNPs in the p21 promoter. We have tested the activity 
of the promoter derived from an LLI and containing a 
cluster of minor alleles in the region between -4547 bp 
and -3489 bp, where a novel p53 binding site has been 
recently identified [7] and found no changes in the basal 
activity or p53 responsiveness of this promoter. It 
Table 3. Frequencies and P‐values for the sixth p21 haplotype containing SNPs rs1801270 and rs1059234 
in the centenarian and control Italian populations. 
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AGGA 0.03725 0.07798 0.03972  rs3176343|rs3176344|rs3176349|rs1801270 
GGGA 0.01198 0.01181 0.98520  rs3176343|rs3176344|rs3176349|rs1801270 
GGTC 0.02854  0.05105  0.17610  rs3176343|rs3176344|rs3176349|rs1801270 
GAGC 0.01811  0.03977  0.12820  rs3176343|rs3176344|rs3176349|rs1801270 
GGGC 0.90410  0.81940  0.00394  rs3176343|rs3176344|rs3176349|rs1801270 
SIX SNP WINDOW        
0.02249  AGGATA 0.03198  0.07607  rs3176343|rs3176344|rs3176349|rs1801270|rs1059234|rs876581 
GGGATA 0.01050  0.01284  0.80000  rs3176343|rs3176344|rs3176349|rs1801270|rs1059234|rs876581 
GGTCCG 0.02906  0.05134  0.18560  rs3176343|rs3176344|rs3176349|rs1801270|rs1059234|rs876581 
GAGCCG 0.01844  0.03970  0.13900  rs3176343|rs3176344|rs3176349|rs1801270|rs1059234|rs876581 
0.00211  GGGCCG 0.91000  0.82000  rs3176343|rs3176344|rs3176349|rs1801270|rs1059234|rs876581 
 should be noted, however, that there are many p53 
independent physiological signals that induce p21, 
where the response of the two alleles may potentially be 
different. Interestingly the p21 promoter is induced by 
some signals involved in stress response and inflame-
mation (such as TGFβ, INFγ, IL-6) that, as discussed 
elsewhere, contribute to the pathogenesis of many age-
















































In a large case-control design study, we have compared 
the frequency of 41 SNPs spanning the p21 gene 
between large populations of LLI and younger Italian 
individuals. Only two of 41 SNPs showed a statistically 
significant difference between the two populations, and 
remarkably, these were the only two exon-derived 
SNPs. A 6-SNP haplotype comprising the common 
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One of these exonic SNPs (rs1801270) changes the 
amino acid sequence of p21 from Ser to Arg at codon 31, 
and the other (rs1059234) leads to a C->T transition 20 
nucleotides downstream of the stop codon in the 3’ 
untranslated region. Remarkably, several studies sug-
gested that the rare alleles of these two SNPs may play a 
role in different types of cancer [12-17]. In particular, Li 
et al. [12] have shown that, in non-Hispanic whites, the  
rare versions of the rs1801270 and rs1059234 alleles are 
associated to an increased risk susceptibility to squamous 
cell carcinoma, individually and in combination. In 
addition, Mousses at al. [18] observed that the rare alleles 
of these two SNPs were under-represented in breast 
cancer and sarcoma patients whose tumors possessed 
somatic p53 mutations, as compared to tumors without 
p53 mutations, suggesting that these alleles could 
influence p21 functions in a p53-independent manner.  
 
According to the data in the NCBI database (Entrez 
SNP), the allele frequency distribution of the SNPs 
rs1801270 and rs1059234 is highly variable and ethnic-
specific. The frequency of the rs1801270 minor allele 
varies from 0.021 (Europeans) to 0.47 (Asians) with 
African-Americans, Sub-Saharan Africans, and 
Hispanics having intermediate values. Similar values 
are found for the rs1059234 rare allele, whose 
frequencies vary from 0.021 (Europeans) to 0.45 
(Asians), with African-Americans, Sub-Saharan 
Africans, and Hispanics also having intermediate 
values. This high ethnicity-related variability can 
greatly complicate the interpretation of disease-
associated studies, especially those conducted in multi-
ethnic societies. In our large-scale study, we have used 
a relatively homogenous Italian population. Our results 
suggest that the presence of the rs1801270 and 
rs1059234 rare alleles combined may be detrimental to 
longevity and therefore negatively selected in Italian 
LLI.  Further large-scale studies could be useful to 
compensate for genetic heterogeneity within the Italian 
population and to clarify the potential role of these 
SNPs in limiting the lifespan. 
 
The mechanisms underlying the potential detrimental 
effect of the rare alleles of rs1801270 and rs1059234 
are presently unknown. The obvious hypotheses are that 
the amino acid change at codon 31, which was proposed 
to abolish p21 phosphorylation at Ser 31 [19], could 
modulate its abilities to arrest the cell cycle or to induce 
transcription of genes implicated in age-related 
diseases, and that a nucleotide change in the 3’ UTR 
could affect p21 mRNA stability or translational 
efficiency. These possibilities remain to be tested in 
future studies. 
Longevity in humans can be defined as a multifactorial 
condition to which both genetic and environmental 
factors are likely to contribute. Twin studies have 
shown that genetic differences account for about a 
quarter of the variance in adult human lifespan. Despite 
the challenges of studying complex traits such as 
lifespan, studies have been reporting alleles that were 
significantly associated with human longevity. One of 
the best examples is APOE whose association has been 
reproduced consistently [20-22]. The compression of 
morbidity hypothesis proposed by James Fries in 1980 
[23] postulates that as the limit of human lifespan is 
approached, the onset and duration of lethal impairment 
compresses toward the end of life. This ‘compression’ 
is observed in the majority of centenarians who are 
often spared from age-related diseases, specifically 
cardiovascular disease, Alzheimer disease, diabetes 
mellitus, and cancer.  To achieve their extreme age, 
centenarians likely lack numerous gene variants that are 
associated with age-related diseases and they may be 
more likely to carry protective variants as well. Our 
finding that the frequency of specific minor alleles of 
p21 is decreased among Italian centenarians lends 
additional support to this concept.  
 
MATERIALS AND METHODS 
 
Subjects. In the pilot study we used ten DNA samples 
from LLI over 90 y.o. (white Americans of European 
descent), including five females and five males. The 
DNA samples, obtained from the NIA Aging Cell 
Repository DNA panel, were obtained from CORIELL 
bank (Camden, NJ). The second group of samples 
comprised DNA from 92 non-centenarian subjects, 
belonging to Utah/CEPH population, provided by 
CORIELL bank. These samples were initially collected 
from Utah residents with ancestry from northern and 
western Europe. In the large case-control study, 184 
Italians with exceptional longevity (mean age, 
100.88±1.77 years) and a control group (38.97±12.21) 
were recruited by the Bologna group in Central Italy, 
after checking for ethnicity and ancestor origins.  The 
sex ratio in the Italian samples was 7 female to 1 male 
in the centenarian group and 2:1 in the control group. A 
full socioeconomic, quality of life and health status 
assessment was performed. Primary criteria for 
inclusion in the study were good health (for cente-
narians, subjects categorized A or B according to 
Franceschi et al. [24] were included), physical activity 
and absence of major diseases. 
 
p21 genotyping. We sequenced the three exons (68 bp, 
450 bp, 1600 bp) and a 5 kb promoter region of the p21 
(CDKN1A) gene in the DNA of ten LLI. The exons and 
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fragments of ~ 400 bp each. The PCR primer pairs are 
listed in Table 4, where p21pro.1 is the furthest from the 
transcription start site. Primers were designed using the 
primer3 software available at http://frodo.wi.mit.edu. 
The primers were sized between 22-24 bases with a Tm 
of 69-71
oC and a GC content of 40-60 %. The primers 
were checked for loops, hairpins and 3’ complemen-
tarity. The selected primers were synthesized by 
idtDNA (Coralville, IA). The genomic DNA templates 
were added to a master mix containing 2 μl of each   
primer (10 μM), 5 μl Buffer (New England Biolabs, 
Ipswich, MA), 2 μl of Taq polymerase (Invitrogen), and 
water to the volume of 50 μl. The following PCR 
profile was used: preincubation for 2 min at 96°C, 40 
cycles of 30 sec at 95°C, 30 sec at the primer-specific 







































lowed by final incubation for 5 min at 72°C. Once 
amplified, the fragments were purified with Millipore  
columns (Millipore Billerica, MA) and then sequenced. 
Sequencing was performed with ABI 3730 DNA 
analyzer, using a Big Dye protocol with Zymo column-
purified products. Complete sequences were aligned, 
assembled and compared using the Clone Manager 
program. For verification, visual inspection of sequence 
profiles for each candidate SNP was carried out. At least 
two overlapping DNA templates amplified with different 
primers were used for identification of each candidate 
SNP. In addition to the SNP candidate approach, the 
latest data available on the HapMap were analyzed, in 
order to select an appropriate number of tagSNPs to 
cover at least 90% of the genetic information in the locus 
(r2=0.9 and MAF>0.05). The tagSNP and candidate SNP 







































Name Sequence  TM 
p21.exon1.R  AAGGCGAGCTCCCAGAAC  60° 
p21seq.exon1.F  ACTGGGGGAGGAGGGAAGT    
p21seq.exon2.F  ACCAGCTGGAAGGAGTGAGA  60° 
p21seq.exon2.R   GTCTTTGCTGCCTACTTGC           
p21seq.exon3.F1  TGCGGTGATGGATAAAATCA  58° 
p21seq.exon3.R1  GAAAAGGAGAACACGGGATG    
p21seq.exon3.F2  TCCTAAGAGTGCTGGGCATT  60° 
p21seq.exon3.R2  GCCCTTCTTCTTGTGTGTCC    
p21seq.exon3.F3  TCTTCTCCAGCTGGGCTCT  58° 
p21seq.exon3.R3  CCCAAAAGCCCATTTATTTG    
p21pro1.r  GGGGCTGCCTATGTAGTGAA   58°+ dmso 
p21pro1.F  GTGCCACAGTTCACAAGTGC    
p21pro2.f  TTTGCTTCTGGGCAGAACTT  58° 
p21pro2.r  CAGAGCCAGGATGAATTGGT                         
P21.pro.3.f  GATGTTGTTAGAGCCAGGAACAG     54° 
P21.pro.3.r ATCAAGGCATAAAAATTTCATTGTG     
P21pro4f                      AAAAGGTTTTTGAATGAATGGATG  58.5°+dmso 
P21pro4r.                     AGAAGAGGCGGAACAAAGATAGAA    
P21pro5f.                     CACGCCCGGCCAGTATATATT TTT      58 °+ dmso 
P21pro5r.    GACAAAATAGCCACCAGCCTCTTCT    
p21pro6.f  CACCTTTCACCATTCCCCTA  58° 
p21pro6.r  AGGGCTGGTTGTCAAATGTC    
p21pro7.f  TGCATGGTTGCAAACTTTTT  54° 
p21pro7.r  TCACCTTTGCCTCCTTTCTG    
p21pro8.f  AGGTCAGCTGCGTTAGAGGA  58° 
p21pro8.r  GGAAGGAGGGAATTGGAGAG    
p21pro9.f  GGAGGCAAAAGTCCTGTGTT  54° 
p21pro9.r  ACATTTCCCCACGAAGTGAG    
p21pro10.f  TCTAGGTGCTCCAGGTGCTT  58° +dmso 
p21pro10.r  CTGTGAACGCAGCACACAC    
p21pro11.f  CCGAAGTCAGTTCCTTGTGG  54° 
p21pro11.r  GCTTCCTTGGGAACAAACTG    
Table 4. Primer sequences and TM for amplifying the p21 gene. 
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chip-based matrix assisted laser desorption/ionization 
time-of-flight MS (DNA MASSARRAY). This tech-
nology performs allele-specific single-base primer 
extension reactions, which allow differentiation of 
homozygous normal, heterozygous mutant and homo-
zygous mutant samples (iPLEX assay).   The 
MassEXTEND primers anneal up to the polymorphic 
site and are extended with one single base. The allele 
product masses depend on the SNP allele base and thus 
they are easily distinguished with the mass 
spectrometer. DNA of the Utah/CEPH population was 
analyzed as a service by Sequenom (San Diego, CA) on 
PCR-derived extension products from individual DNA 
samples. Large-scale analysis of Italian samples was 
performed by the Bologna group. Cases and controls 
were always analyzed on the same chip to avoid 
potential artifacts caused by chip–specific miscalls. 
 
Plasmid constructs.  The plasmid p21-PGL.4.10-luc 
containing the 5 kb p21 promoter comprising the 
common alleles and driving firefly luciferase expression 
has been previously described [7].  This plasmid was 
used to replace a cluster of common SNP alleles in the 
promoter with the minor alleles, contained within a 
fragment of ~2.1 kb, which was amplified by double-
round PCR from genomic DNA of a LLI. PCR was 
carried out using a proofreading polymerase, Phusion™ 
Hot Start High-Fidelity DNA Polymerase (New 
England Biolabs, Ipswich, MA). The primed template 
was pre-formed in the presence of 5X Phusion GC 
buffer (New England Biolabs, Ipswich, MA) and 200 
µM of each dNTP, 0.5 μM primers, and 1 U of Phusion 
DNA polymerase. The template being GC-rich, 3% 
DMSO was added to optimize the product yield. The 
samples were incubated as follows: preincubation for 30 
sec at 98°C, 30 cycles of 10 sec at 98°C, 30 sec at 66°C 
and 3 min at 72°C and one final incubation for 5 min at 
72°C. In the first round, the 5kb PCR product of the p21 
promoter was amplified using the following primers: 
p21-4997F   TACAAACATTGGGTGGGGCGAGTC 
p21-R-44   CTCCGGCTCCACAAGGAACTGACTT 
In the second round, this PCR product was used as a 
template to generate a PCR product of ~2.1 kb using the 
following primers: 
p21-4497F   TACAAACATTGGGTGGGG CGAGTC 
p21-5R   GACAAAATAGCCACCAGCCTCTTCT 
The latter PCR product was digested with AatII and Sph 
restriction enzymes (New England Biolabs), and cloned 
into p21-PGL.4.10-luc plasmid digested with the same 
enzymes, replacing the corresponding fragment 
containing the common alleles. The resulting plasmid 
was sequence-verified and designated p21R-luc.  
 
Promoter analysis by transient transfection. HCT116  
colon carcinoma cells, both wild type and p53-/- 
sublines [8] (a gift of Dr. B. Vogelstein, Johns Hopkins 
University) were grown in DMEM with Earle's salts 
supplemented with 10% FCS and 2 mM L-glutamine in 
a humidified 95% air 5% CO2 incubator. Cells were 
seeded in 12-well tissue culture plates for 24 h prior to 
transfection. When  70% confluent, the cells were 
transfected with 1 μg of the indicated promoter–reporter 
plasmids, together with pRL–TK Renilla luciferase 
expressing plasmid (Promega, Madison, WI) to normal-
ize for transfection efficiency, at a ratio of 10:1 test 
vector:standard vector. Transfections were performed in 
triplicate, using FuGENE6 (Roche Molecular Bio-
chemicals). A precipitate was formed using 3 μl of 
FuGENE6/μg of transfected DNA and the transfection 
mixture was diluted up to 1 ml with serum-free 
medium. After incubation at 22°C for 10 min, the 
DNA/FuGENE6 mixture was added to cells. Cells were 
harvested 48 h after transfection, and firefly and Renilla 
luciferase activities were measured.  
 
Statistical analysis.  We tested departure
  from Hardy-
Weinberg equilibrium [25] in the controls by a 
2 test
 
using P = 0.01 as threshold. This threshold was chosen 
based
 on anticonservativeness of this test as noted by 
Wigginton [25]. All SNPs (except for rs4711458, 
rs4714003, CDKN1A7, rs6920453) were in Hardy-
Weinberg
 equilibrium. Each SNP was tested both with 
basic association testing based on comparing allele 
frequencies between cases and controls (asymptotic and 
empirical p-value to control for multiple testing), and 
with Conchran-Armitage trend test in a dominant, 
recessive and general model. 
 
Multi-locus haplotype analysis was performed by using 
a sliding-window approach implemented in PLINK [26] 
for multi-loci of 4 or 6 SNPs size.  Multimarker  haplo- 
types have been estimated by using the E-M algorithm 
implemented in the software. An LD map of the region 
has been produced by using the software Haploview 
[27] in order to identify LD blocks within the typed 
markers. The haplotype blocks identified have been 
tested in the same way, i.e. phased and used for 
frequency estimation by E-M algorithm and chi-square 
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